Company intelligence / Profile preview

Mytosynth Nutraceuticals

Wilmington, Delaware, United States

Ownership: Private
Development stage: Other

Overview

Mytosynth is a nutraceutical company specializing in mitochondrial health and cellular longevity. The company develops and markets high-potency supplements designed to optimize mitochondrial function, enhance cellular energy production, and support healthy aging. Their flagship formulations typically include a synergistic blend of ingredients such as Urolithin A, CoQ10, PQQ, and NAD+ precursors, targeting key pathways like mitochondrial biogenesis and mitophagy. Mytosynth aims to bridge the gap between clinical research and consumer wellness by providing science-backed solutions for proactive health management.

Therapeutic areas: Rare DiseasesNeurologyOther
Modalities: Small moleculeSupplements
Industry: Food & Nutrition

Beyond the preview

Go deeper on Mytosynth Nutraceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mytosynth Nutraceuticals.

Explore the full profile